NetraMark
Joseph Geraci is a highly accomplished professional with extensive experience in technology and scientific leadership across various organizations. Currently serving as the Chief Technology Officer and Chief Scientific Officer at NetraMark and Nurosene Inc., Joseph has been pivotal in enhancing clinical trials and empowering AI for pharmaceutical companies. With a solid background in academia as an Assistant Professor at Queen's University since 2011, Joseph has contributed to the field of healthcare through roles like Project Scientist at CAMH, Machine Learning Lead at CAN-BIND, and Chief Science Officer at Open Source Health Inc. Notable prior experience includes innovative contributions at Equifax Canada and the development of computational approaches at Modecular Inc. Joseph holds multiple advanced degrees, including a PhD in Mathematical Physics and Applied Mathematics from the University of Southern California and the University of Toronto, respectively.
This person is not in any teams
NetraMark
NetraMark combines proprietary QML/ML algorithms with cross-domain expertise to bring ML commercialization into reality, starting with the pharmaceutical space in drug development where we utilize large and small data in order to help pharmaceutical companies understand their patient populations better. Our technology allows for the utilization of phase II data in order to optimize phase III trials from the vantage of their specific patient population.